Skip to content

Released Mar 12, 2020, before the open

10-K filed Mar 12, 2020, 72 days after period end · 0001104659-20-032540

Q4 2019 · 10-K
Revenue$17.76Mderived−34.3% vs Q4 2018+24.6% vs Q3 2019
Net Income$291.00KN/M vs Q4 2018N/M vs Q3 2019
EPS Diluted$0.02N/M vs Q4 2018N/M vs Q3 2019
Operating Income$2,200,000N/M
Operating Cash Flowderived-$3,687,000N/M
Free Cash Flowderived-$3,715,000N/M
Margins · derived
Operating margin12.4%+26.0 pt vs Q4 2018
Net margin1.6%+21.8 pt vs Q4 2018

What the release said

The release

Same quarter

MetricQ4 2019Q4 2018Q4 2017derived from reported figuresQ4 2016derived from reported figures
Revenue$17.76M$27.02M$4.31M$2.08M
Net Income$291.00K-$5.43M-$13.31M-$2.62M
EPS Diluted$0.02-$0.40——

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR